Status:
COMPLETED
Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection
Lead Sponsor:
Columbia University
Collaborating Sponsors:
GlaxoSmithKline
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Staphylococcus Aureus
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Staphylococcus aureus is a bacteria that causes serious, often life threatening infections including pneumonia, wound, and bloodstream infections. Persons with AIDS are at high risk for S. aureus infe...
Detailed Description
This was a randomized double-blinded placebo controlled trial. Subjects were treated with intranasal mupirocin or placebo on a monthly basis and tested for nasal colonization a month after each treatm...
Eligibility Criteria
Inclusion
- Resident at Project Samaritan Inc. (PSI)
Exclusion
- Past hypersensitivity to mupirocin or glycerol
- Pregnancy
- Lactation
- Expected discharge from PSI in the following month
- Treatment with intranasal mupirocin within the preceding two months
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00801879
Start Date
September 1 2003
End Date
April 1 2006
Last Update
October 29 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University
New York, New York, United States, 10032
2
Project Samaritan Inc.
The Bronx, New York, United States, 10452